British company Cannaray has collaborated with Canadian giant Aphria Inc to fill its first UK medical cannabis prescription

The prescription was filled, free of charge, for Jorja Emerson, a three-year-old girl suffering from severe epilepsy.

Jorja was denied treatment on the NHS which forced her father Robin to travel from Dundonald in Northern Ireland to access treatment in London at a cost of €1,000 per month.

Cannaray CEO, Scott Maguire, commented:

“Working with the medical community to provide specialist support and access to cannabis-based drugs for patients in dire need of this treatment is fundamental to our strategy.

“We are pleased to assist Robin in accessing treatment for his daughter and we will continue to drive for broader and continuous cannabis access for patients.”

Cannaray has also announced a new round of expansion in 2020 as a result of the £7.8 million Series A funding, starting with the appointment of Gregor Zorn as Chief Scientific Officer.

Zorn is one of the leading names in medical cannabis treatment and education.

He said:

“Improvements in technology and dedicated research have allowed us to start understanding the full potential of this healing plant.

“I am honoured to be joining this amazing team of professionals and I am looking forward to adding my expertise in achieving Cannaray’s vision of providing patients with the best medical cannabis and cannabinoid-based products.”

Cannaray will add a series of pain specialists, neurologists and pharmacists to their team in the coming year.

Cannaray’s Scientific Advisory Board includes specialists in multiple sclerosis, chemo-induced nausea and vomiting, epilepsy, chronic pain and Tourette’s.